Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma
NCT00248534Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2005
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2005; status: terminated.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00248534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248534.